Facets (new session)
Description
Metadata
Settings
owl:sameAs
Inference Rule:
b3s
b3sifp
dbprdf-label
facets
http://dbpedia.org/resource/inference/rules/dbpedia#
http://dbpedia.org/resource/inference/rules/opencyc#
http://dbpedia.org/resource/inference/rules/umbel#
http://dbpedia.org/resource/inference/rules/yago#
http://dbpedia.org/schema/property_rules#
http://www.ontologyportal.org/inference/rules/SUMO#
http://www.ontologyportal.org/inference/rules/WordNet#
http://www.w3.org/2002/07/owl#
ldp
oplweb
skos-trans
virtrdf-label
None
About:
Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
schema:ScholarlyArticle
, within Data Space :
covidontheweb.inria.fr
associated with source
document(s)
Type:
Academic Article
research paper
schema:ScholarlyArticle
New Facet based on Instances of this Class
Attributes
Values
type
Academic Article
research paper
schema:ScholarlyArticle
isDefinedBy
Covid-on-the-Web dataset
has title
Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient
Creator
Ng, C
David, |
Johnson, Doug
Rentsch, Clarissa
Al-Ani, Aysha
Campbell, Sian
Christensen, |
Finlay, |
Garg, |
Heerasing, |
Macrae, A
Prentice, E
Ralley, |
Rubin, T
Sasadeusz, |
Siew, |
Zaid Ardalan, |
Source
Medline; PMC; WHO
abstract
BACKGROUND: The current COVID‐19 pandemic, caused by SARS‐CoV‐2, has emerged as a public health emergency. All nations are seriously challenged as the virus spreads rapidly across the globe with no regard for borders. The primary management of IBD involves treating uncontrolled inflammation with most patients requiring immune‐based therapies. However, these therapies may weaken the immune system and potentially place IBD patients at increased risk of infections and infectious complications including those from COVID‐19. AIM: To summarise the scale of the COVID‐19 pandemic, review unique concerns regarding IBD management and infection risk during the pandemic and assess COVID‐19 management options and drug interactions in the IBD population. METHODS: A literature review on IBD, SARS‐CoV‐2 and COVID‐19 was undertaken and relevant literature was summarised and critically examined. RESULTS: IBD patients do not appear to be more susceptible to SARS‐CoV‐2 infection and there is no evidence of an association between IBD therapies and increased risk of COVID‐19. IBD medication adherence should be encouraged to prevent disease flare but where possible high‐dose systemic corticosteroids should be avoided. Patients should exercise social distancing, optimise co‐morbidities and be up to date with influenza and pneumococcal vaccines. If a patient develops COVID‐19, immune suppressing medications should be withheld until infection resolution and if trial medications for COVID‐19 are being considered, potential drug interactions should be checked. CONCLUSION: IBD patient management presents a challenge in the current COVID‐19 pandemic. The primary focus should remain on keeping bowel inflammation controlled and encouraging medication adherence.
has issue date
2020-05-26
(
xsd:dateTime
)
bibo:doi
10.1111/apt.15779
bibo:pmid
32348598
has license
no-cc
sha1sum (hex)
8ab467c2f87ef7d6eeb625b9f970c18595970fb8
schema:url
https://doi.org/10.1111/apt.15779
resource representing a document's title
Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient
has PubMed Central identifier
PMC7267115
has PubMed identifier
32348598
schema:publication
Aliment Pharmacol Ther
resource representing a document's body
covid:8ab467c2f87ef7d6eeb625b9f970c18595970fb8#body_text
is
schema:about
of
named entity 'therapies'
named entity 'avoided'
named entity 'All nations'
named entity 'primary'
named entity 'evidence'
named entity 'literature'
named entity 'susceptible'
named entity 'develops'
named entity 'options'
named entity 'LITERATURE'
named entity 'RESULTS'
named entity 'EMERGENCY'
named entity 'CO-MORBIDITIES'
named entity 'APPEAR'
named entity 'INFECTIONS'
named entity 'IBD'
named entity 'therapies'
named entity 'infection'
named entity 'drug interactions'
named entity 'rapidly'
named entity 'virus'
named entity 'Results'
named entity 'medication adherence'
named entity 'disease'
named entity 'The'
named entity 'medication adherence'
named entity 'inflammation'
named entity 'pandemic'
named entity 'drug interactions'
named entity 'COVID-19 pandemic'
named entity 'COVID-19'
named entity 'influenza'
named entity 'drug interactions'
named entity 'COVID'
named entity 'SARS-CoV-2'
named entity 'COVID-19'
named entity 'pneumococcal vaccines'
named entity 'virus'
named entity 'social distancing'
named entity 'IBD'
named entity 'inflammation'
named entity 'IBD'
named entity 'Patients'
named entity 'COVID'
named entity 'leukopenia'
named entity 'COVID'
named entity 'infection'
named entity 'TNF antagonist'
named entity 'biopsy'
named entity 'anosmia'
named entity 'meta-analysis'
named entity 'endoscopy'
named entity 'COVID'
named entity 'infection'
named entity 'epidemiologic'
named entity 'Sulfasalazine'
named entity 'inflammatory'
named entity 'virus'
named entity 'Favipiravir'
named entity 'vitamin'
named entity 'IBD'
named entity 'case-fatality rate'
named entity 'SARS-CoV-2'
named entity 'COVID-19'
named entity 'upper respiratory tract infections'
◂◂ First
◂ Prev
Next ▸
Last ▸▸
Page 1 of 8
Go
Faceted Search & Find service v1.13.91 as of Mar 24 2020
Alternative Linked Data Documents:
Sponger
|
ODE
Content Formats:
RDF
ODATA
Microdata
About
OpenLink Virtuoso
version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software